Forum Agenda

July 23,09:00–17:30

CNS Novel Drug R&D Session

Stay tuned

Conference Planning
Fei Guo:Founder, Hanshu Biotechnology
Dawei Yuan:Founder, Chairman and General Manager, Beijing Quark Pharmaceutical Group
Huaqiong Shen:Founder & CEO, Neushen Pharmaceuticals
    
Conference Hosting
Rui Huang:Deputy General Manager, Hanshu Biotechnology

 

09:00-09:05 Message
Yutian Wang:Professor, Shangsi Neuroscience Center, Fudan University;Fellow of the Royal Society of Canada;Founder & Chairman, Purui Pharmaceuticals

 

09:05-09:30 Memory Reactivation Underlies Experience-Dependent Adaptive Regulation of Sleep
Yi Zhong:Professor, School of Life Sciences, Tsinghua University; Principal Investigator, Tsinghua-IDG/McGovern Institute for Brain Research; Founder, Chairman & Chief Scientist, Beijing Joekai Biotechnology

 

09:30-09:45 Research and Development of New Molecular Entity (NME) Drugs for Schizophrenia
Jingwei Tian:Executive Vice President of R&D, Luye Pharma Group; Dean, School of Pharmacy, Yantai University

 

09:45-10:00 PRODEGRE ATLAS – A Protein Degradation Innovation Platform to Enable Breakthrough Therapies for CNS Disorders
Shen Tan:Co-founder & CEO, Purui Pharmaceuticals

 

10:00-10:15 Research Progress of the AMCDx Platform (Cyclodextrin Analogues) in the CNS Field
Youmao Qi:Chairman, Omer Pharmaceuticals; Director of the Academician Workstation; Chief Scientist

 

10:15-10:35 Break

 

10:35-10:50 Discovery and Development of a Novel Non-Opioid Potent Analgesic Agent with Dual Target Mechanism
Xijun SHENG:Head of Innovative Research Center, YiChang Humanwell Pharmaceutical Co.,Ltd.

 

10:50-11:05 Frontier Technology in Innovative CNS Drug Development
Isaac Cheng:VP Research of  suntec medical

 

11:05-11:20 Disease-Modifying Therapy for Parkinson's Disease
Yang Song:CEO &CMO ofHygtia Therapeutics

 

11:20-12:10 Roundtable: The Future of CNS New Drug R&D
Fei Guo(Host):Founder, Hanshu Biotechnology
Qun Fang:Chief Scientific Officer (CSO), Yisi Biotechnology; Head of Brain Science Innovation R&D Center
Qun Li:General Manager, Saipute
Bingjie Wang:Chief Business Officer (CBO), Iongen Therapeutics Co., Ltd.
Deqiang Niu: Co-founder & CEO of Kehui Zhihao (COHITON)

 

12:10-13:30 Lunch Break

 

Conference Hosting
David.yuan:Chairman, Quark Pharmaceutical Group

 

13:30-13:50 The Path to Clinical Translation of Innovative Biopharmaceuticals – Opportunities, Challenges, and Collaboration
Tianmei Si:Vice President, Peking University Sixth Hospital; Deputy Director, National Institute of Mental Health

 

13:50-14:10 Research on JAK-STAT Therapy for Neurodegenerative Diseases
Xinyuan Fu:Founder of GenEros Biopharma; Director of the Institute of Immunological Inflammation, West China Hospital of Sichuan University; Director of the Laboratory of Human Diseases and Immunotherapy

 

14:10-14:30 Director of Clinical Research Center, Shanghai Mental Health Center; Executive Director of National Drug Clinical Trial Institution
Huafang Li : Director of the Clinical Research Center, Shanghai Mental Health Center; Executive Director of the National Drug Clinical Trial Institution


14:30-14:45 Expanding Extrahepatic Applications of Oligonucleotide Therapeutics – Research Progress in CNS Diseases
Shan Gao:Senior Vice President & Chief Scientific Officer (CSO), Ribo Life Science

 

14:45-15:00 Medical Uses and Market Prospects of Modified Psychedelics – Perspectives from the FDA's New Guidance and Trump's Executive Order
Joan Shen:Founder & CEO, NeuShen Therapeutics

 

15:00-15:15 Universal iPSC-Derived Cell Therapy for Neurological Injury Disorders
Jing Fan:Founder & CEO, Hopstem Biosciences

 

15:15-15:35 Break

 

15:35-15:50 Preliminary Validation of iPSC-Derived Therapies for CNS Disorders Based on the SISBAR Core Technology Platform
Lanlin Wu:CEO, Unicell Biotechnology

 

15:50-16:05 Clinical Study on Deep Cervical Lymphatic Venous Anastomosis for Alzheimer's Disease
Ping Luan:Director and Chief Scientist of the National Advanced Cognitive Center (Department of Alzheimer's Disease Clinical Research Center,  Guangdong Second Provincial General Hospital )

 

16:05-16:20 Development and Global Commercialization Pathway of QP001 Injection
Sen Yu:Vice President, Qingpu Biopharma

 

16:20-16:35 Mouse Models in Neuroscience: Bridging Efficacy to the Clinic - A CriticalPiece in Accelerating CNS Drug Translation
Rikki FENG:Chief Scientist, Neuroscience Pipeline, GemPharmatech

 

16:35-16:50 Overcoming the Blood-Brain Barrier with Theranostic Bubbles and Ultrasound
Mr. Michael Paumen:WellThera Director

 

16:50-17:30 Roundtable: The Globalization Path of China's CNS Innovative Drugs
Xiaochun Huang(Host):VP,Beijing Quark Pharmaceutical Group
Yongjiang Hei:Founder, Huisibo Biopharma

Jun Tan:Co-founderand Chief Scientific Advisor ofAnyu Biotechnology (Hangzhou) Co., Ltd
William:Former General Manager, Joekai Biotechnology
Mengqi Fan:Mengqi Fan: CEO, Mabwell Biosciences, Chairman SA